Bioventus BVS Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Net Sales by Business | ||||||
| International Segment | $68.28M+3.5% | $65.99M0.0% | $66.01M-1.1% | $66.73M+3.2% | $64.65M-2.7% | |
| U.S. Segment | $508.02M+1.2% | $502.1M+0.9% | $497.82M+0.1% | $497.41M-1.1% | $503.05M-0.7% | |
| Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization And Other Non-Operating Items by Business | ||||||
| International Segment | $15.93M+4.0% | $15.31M+6.1% | $14.44M-4.8% | $15.17M+18.9% | $12.75M-5.3% | |
| U.S. Segment | $105.05M+4.0% | $100.97M+8.1% | $93.38M+4.2% | $89.61M-3.4% | $92.72M-2.8% | |
| Adjusted other segment expense by Business | ||||||
| International Segment | $66K-64.9% | $188K+263% | -$115K+81.9% | -$637K+7.8% | -$691K-70.6% | |
| U.S. Segment | $395K-74.5% | $1.55M+8.6% | $1.42M+30.0% | $1.1M+41.5% | $774K+320% | |
| Adjusted cost of sales by Business | ||||||
| International Segment | $26.03M+4.7% | $24.86M+2.1% | $24.34M+1.6% | $23.96M+0.2% | $23.9M-1.2% | |
| U.S. Segment | $113.33M-0.4% | $113.82M-1.8% | $115.96M-1.0% | $117.13M-1.4% | $118.77M-0.2% | |
| Adjusted research and development expense by Business | ||||||
| International Segment | $38K-7.3% | $41K+17.1% | $35K-20.5% | $44K+29.4% | $34K-17.1% | |
| U.S. Segment | $10.73M-4.8% | $11.27M-2.7% | $11.58M-6.9% | $12.44M-4.6% | $13.04M-0.8% | |
| Adjusted general and administrative expense by Business | ||||||
| International Segment | $9.94M+6.6% | $9.33M-19.4% | $11.57M-9.7% | $12.82M-7.4% | $13.84M-7.4% | |
| U.S. Segment | $98.42M+0.9% | $97.5M+0.7% | $96.83M-0.9% | $97.75M+0.2% | $97.56M0.0% | |
| Adjusted selling expense by Business | ||||||
| International Segment | $12.81M+1.0% | $12.69M+3.8% | $12.22M+1.0% | $12.1M+4.5% | $11.58M+3.1% | |
| U.S. Segment | $155.6M+2.3% | $152.08M-0.8% | $153.37M-0.5% | $154.13M-0.9% | $155.52M-1.4% | |
| Adjusted marketing expense by Business | ||||||
| International Segment | $3.47M-3.3% | $3.59M+2.0% | $3.52M+7.4% | $3.27M+1.3% | $3.23M+7.6% | |
| U.S. Segment | $24.5M-1.7% | $24.92M-1.4% | $25.28M0.0% | $25.27M+2.5% | $24.66M+1.8% | |
| Total Net Sales by Product | ||||||
| Pain Treatments | $283.57M+1.6% | $279.06M+3.9% | $268.62M+1.5% | $264.57M+0.4% | $263.52M+0.9% | |
| Restorative Therapies | $86.29M+1.1% | $85.37M-8.6% | $93.37M-8.5% | $102M-8.9% | $111.99M-8.8% | |
| Surgical Solutions | $206.45M+1.4% | $203.65M+0.9% | $201.84M+2.2% | $197.57M+2.8% | $192.2M+1.6% | |
| Total Net Sales by Geography | ||||||
| International | $68.28M+3.5% | $65.99M0.0% | $66.01M-1.1% | $66.73M+3.2% | $64.65M-2.7% | |
| U.S. | $508.02M+1.2% | $502.1M+0.9% | $497.82M+0.1% | $497.41M-1.1% | $503.05M-0.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bioventus break its business down?
- Bioventus (BVS) reports total net sales by business across 2 parts — International Segment and U.S. Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Bioventus's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bioventus's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
